SG11201808242UA - Methods for inhibiting angiogenesis in a subject in need thereof - Google Patents
Methods for inhibiting angiogenesis in a subject in need thereofInfo
- Publication number
- SG11201808242UA SG11201808242UA SG11201808242UA SG11201808242UA SG11201808242UA SG 11201808242U A SG11201808242U A SG 11201808242UA SG 11201808242U A SG11201808242U A SG 11201808242UA SG 11201808242U A SG11201808242U A SG 11201808242UA SG 11201808242U A SG11201808242U A SG 11201808242UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- masp
- subject
- methods
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract 4
- 230000033115 angiogenesis Effects 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 abstract 3
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 abstract 3
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 241001502883 Marcia Species 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER (19) World Intellectual Property -, Organization International Bureau 0.. .... .. (43) International Publication Date ...... ... 5 October 2017 (05.10.2017) IN I PO I P CT THE PATENT COOPERATION TREATY (PCT) MD 1101111 0 HEIN MEM 01E010 111110010111 11101101111101111 MI (10) International Publication Number WO 2017/173290 Al (51) (21) (22) (25) Filing Language: (26) Publication Language: (30) (71) (72) (71) International Patent Classification: A61K 39/395 (2006.01) A61P 27/02 (2006.01) A61P 7/00 (2006.01) C07K 16/40 (2006.01) International Application Number: (74) PCT/US2017/025411 International Filing Date: (81) 31 March 2017 (31.03.2017) English English Priority Data: 62/315,857 31 March 2016 (31.03.2016) US Applicants: OMEROS CORPORATION [US/US]; 201 Elliott Avenue West, Seattle, WA 98119 (US). UNIVER- SITY OF LEICESTER [GB/GB]; University Road, Leicester, Leicestershire LE1 7RF (GB). Inventors; and (84) Applicants : DEMOPULOS, Gregory, A. [US/US]; 4845 Forest Avenue SE, Mercer Island, WA 98040 (US). SCHWAEBLE, Hans-Wilhelm [DE/GB]; 36 The Green, Mountsorrel, Leicestershir LE12 7AF (GB). DUDLER, ZA, ZM, ZW. Thomas [CH/US]; 13410 NE 36th Street, Bellevue, WA 98005 (US). TJOELKER, Larry [US/US]; 11731 North- east 145th Street, Kirkland, WA 98034 (US). Agent: KELBON, Marcia; Omeros Corporation, 201 Elli- ott Avenue West, Seattle, WA 98119 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, [Continued on next page] = = — Title: METHODS FOR INHIBITING ANGIOGENESIS o 00 (54) IN A SUBJECT IN NEED THEREOF (57) : In one aspect, the present invention provides methods for preventing, treating, reverting and/or delaying angiogenesis in a mammalian sub- ject suffering from, or at risk for developing, an an- giogenesis-dependent disease or condition, compris- ing administering to the subject an amount of a MASP-2 inhibitory agent effective to inhibit an- giogenesis. In some embodiments of these aspects of the invention, the MASP-2 inhibitory agent is a MASP-2 antibody or fragment thereof. = = ewmw , KOLIIS te:,! COMPaM to vehic;e: * ;),,c,:i...i. ixer,001. — = = - 4t. ea** = — = = 0 0 0 0 0 10 = — = *a* • • = — = = :Fig.10. 11 © C:r ei M IN ,-1 IN ,—, © ei O WO 2017/173290 Al MUNRO DOI 01011MMEMOMMEINEHMON111EHOIMIE DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, — as to the applicant's entitlement to claim the priority of LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, the earlier application (Rule 4.17(iii)) GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: Declarations under Rule 4.17: — with international search report (Art. 21(3)) — as to applicant's entitlement to apply for and be granted — a patent (Rule 4.17(ii)) with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662315857P | 2016-03-31 | 2016-03-31 | |
| PCT/US2017/025411 WO2017173290A1 (en) | 2016-03-31 | 2017-03-31 | Methods for inhibiting angiogenesis in a subject in need thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808242UA true SG11201808242UA (en) | 2018-10-30 |
Family
ID=59959191
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202009886SA SG10202009886SA (en) | 2016-03-31 | 2017-03-31 | Methods for inhibiting angiogenesis in a subject in need thereof |
| SG11201808242UA SG11201808242UA (en) | 2016-03-31 | 2017-03-31 | Methods for inhibiting angiogenesis in a subject in need thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202009886SA SG10202009886SA (en) | 2016-03-31 | 2017-03-31 | Methods for inhibiting angiogenesis in a subject in need thereof |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10870708B2 (en) |
| EP (1) | EP3436072A4 (en) |
| JP (3) | JP6865767B2 (en) |
| KR (3) | KR20230019991A (en) |
| CN (3) | CN109152834A (en) |
| AU (2) | AU2017240129B2 (en) |
| BR (1) | BR112018069732A2 (en) |
| CA (2) | CA3096270A1 (en) |
| CL (1) | CL2018002708A1 (en) |
| EA (2) | EA202191185A1 (en) |
| GE (1) | GEP20237466B (en) |
| IL (2) | IL262021B2 (en) |
| MA (1) | MA44518A (en) |
| MX (2) | MX2018011648A (en) |
| MY (1) | MY195432A (en) |
| NZ (1) | NZ745531A (en) |
| PH (1) | PH12018502046A1 (en) |
| SG (2) | SG10202009886SA (en) |
| WO (1) | WO2017173290A1 (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20170170B1 (en) | 2016-08-31 | 2022-09-15 | Omeros Corp | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods |
| CN107661492A (en) * | 2017-08-31 | 2018-02-06 | 中山大学中山眼科中心 | VEGF B new application |
| CN107537026A (en) * | 2017-08-31 | 2018-01-05 | 中山大学中山眼科中心 | VEGF B application |
| US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| US11433276B2 (en) | 2019-05-10 | 2022-09-06 | Rehab2Fit Technologies, Inc. | Method and system for using artificial intelligence to independently adjust resistance of pedals based on leg strength |
| US11904207B2 (en) | 2019-05-10 | 2024-02-20 | Rehab2Fit Technologies, Inc. | Method and system for using artificial intelligence to present a user interface representing a user's progress in various domains |
| US11957956B2 (en) | 2019-05-10 | 2024-04-16 | Rehab2Fit Technologies, Inc. | System, method and apparatus for rehabilitation and exercise |
| US11957960B2 (en) | 2019-05-10 | 2024-04-16 | Rehab2Fit Technologies Inc. | Method and system for using artificial intelligence to adjust pedal resistance |
| US11896540B2 (en) | 2019-06-24 | 2024-02-13 | Rehab2Fit Technologies, Inc. | Method and system for implementing an exercise protocol for osteogenesis and/or muscular hypertrophy |
| US11071597B2 (en) | 2019-10-03 | 2021-07-27 | Rom Technologies, Inc. | Telemedicine for orthopedic treatment |
| US11955223B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for using artificial intelligence and machine learning to provide an enhanced user interface presenting data pertaining to cardiac health, bariatric health, pulmonary health, and/or cardio-oncologic health for the purpose of performing preventative actions |
| US11955221B2 (en) * | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for using AI/ML to generate treatment plans to stimulate preferred angiogenesis |
| US11887717B2 (en) | 2019-10-03 | 2024-01-30 | Rom Technologies, Inc. | System and method for using AI, machine learning and telemedicine to perform pulmonary rehabilitation via an electromechanical machine |
| US11955220B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for using AI/ML and telemedicine for invasive surgical treatment to determine a cardiac treatment plan that uses an electromechanical machine |
| US11978559B2 (en) | 2019-10-03 | 2024-05-07 | Rom Technologies, Inc. | Systems and methods for remotely-enabled identification of a user infection |
| US11915816B2 (en) | 2019-10-03 | 2024-02-27 | Rom Technologies, Inc. | Systems and methods of using artificial intelligence and machine learning in a telemedical environment to predict user disease states |
| US11923065B2 (en) | 2019-10-03 | 2024-03-05 | Rom Technologies, Inc. | Systems and methods for using artificial intelligence and machine learning to detect abnormal heart rhythms of a user performing a treatment plan with an electromechanical machine |
| US11955222B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for determining, based on advanced metrics of actual performance of an electromechanical machine, medical procedure eligibility in order to ascertain survivability rates and measures of quality-of-life criteria |
| US11961603B2 (en) | 2019-10-03 | 2024-04-16 | Rom Technologies, Inc. | System and method for using AI ML and telemedicine to perform bariatric rehabilitation via an electromechanical machine |
| US11101028B2 (en) | 2019-10-03 | 2021-08-24 | Rom Technologies, Inc. | Method and system using artificial intelligence to monitor user characteristics during a telemedicine session |
| US11075000B2 (en) | 2019-10-03 | 2021-07-27 | Rom Technologies, Inc. | Method and system for using virtual avatars associated with medical professionals during exercise sessions |
| US11069436B2 (en) | 2019-10-03 | 2021-07-20 | Rom Technologies, Inc. | System and method for use of telemedicine-enabled rehabilitative hardware and for encouraging rehabilitative compliance through patient-based virtual shared sessions with patient-enabled mutual encouragement across simulated social networks |
| US11915815B2 (en) | 2019-10-03 | 2024-02-27 | Rom Technologies, Inc. | System and method for using artificial intelligence and machine learning and generic risk factors to improve cardiovascular health such that the need for additional cardiac interventions is mitigated |
| IL293550A (en) | 2019-12-04 | 2022-08-01 | Omeros Corp | Masp-2 inhibitor compounds, compositions comprising same and uses thereof |
| EP4069238A1 (en) | 2019-12-04 | 2022-10-12 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| CA3159159A1 (en) | 2019-12-04 | 2021-06-10 | Neil S. Cutshall | Masp-2 inhibitors and methods of use |
| JP2023504542A (en) | 2019-12-04 | 2023-02-03 | オメロス コーポレーション | MASP-2 inhibitors and methods of use |
| KR20220031412A (en) | 2020-09-04 | 2022-03-11 | 주식회사 엘지에너지솔루션 | Apparatus and method for managing battery |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| WO1989005852A1 (en) | 1987-12-15 | 1989-06-29 | Macphillamy Cummins & Gibson | Ribozymes |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| ATE149841T1 (en) | 1990-01-26 | 1997-03-15 | Immunomedics Inc | VACCINES AGAINST CANCER AND INFECTIOUS DISEASES |
| JP3218637B2 (en) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | Stable aqueous liposome suspension |
| US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| JP2958076B2 (en) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | Multilamellar liposome for gene transfer and gene-captured multilamellar liposome preparation and method for producing the same |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| US7083786B2 (en) | 1997-04-03 | 2006-08-01 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
| US6649592B1 (en) | 2000-01-14 | 2003-11-18 | Science & Technology Corporation @ Unm | Peptide inhibitors of LFA-1/ICAM-1 interaction |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| CA2490007C (en) | 2002-07-19 | 2011-05-24 | Omeros Corporation | Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from |
| SI1625166T1 (en) | 2003-05-12 | 2015-08-31 | Helion Biotech Aps | Antibodies to masp-2 |
| US20130266559A1 (en) | 2004-06-10 | 2013-10-10 | University Of Leicester | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8168584B2 (en) * | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| US11130801B2 (en) | 2011-01-13 | 2021-09-28 | Case Western Reserve University | Method for inhibiting platelet derived growth factor signaling with C3aR or C5aR antibodies |
| KR20220044616A (en) * | 2011-04-08 | 2022-04-08 | 유니버시티 오브 레스터 | Methods for treating conditions associated with masp-2 dependent complement activation |
| EP2704743B1 (en) | 2011-05-04 | 2020-03-11 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement acitivation |
| CN103796667A (en) * | 2011-06-22 | 2014-05-14 | 艾普莱斯制药公司 | Methods of treating chronic disorders with complement inhibitors |
| RS61755B1 (en) * | 2012-06-18 | 2021-05-31 | Omeros Corp | Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders |
| CN111588855A (en) * | 2013-10-17 | 2020-08-28 | 奥默罗斯公司 | Methods for treating conditions associated with MASP-2 dependent complement activation |
-
2017
- 2017-03-31 WO PCT/US2017/025411 patent/WO2017173290A1/en active Application Filing
- 2017-03-31 CN CN201780021420.XA patent/CN109152834A/en active Pending
- 2017-03-31 SG SG10202009886SA patent/SG10202009886SA/en unknown
- 2017-03-31 CN CN202210704608.7A patent/CN115137816A/en active Pending
- 2017-03-31 KR KR1020237002512A patent/KR20230019991A/en not_active Application Discontinuation
- 2017-03-31 US US15/476,154 patent/US10870708B2/en active Active
- 2017-03-31 NZ NZ745531A patent/NZ745531A/en unknown
- 2017-03-31 KR KR1020187030563A patent/KR20180128941A/en not_active IP Right Cessation
- 2017-03-31 CA CA3096270A patent/CA3096270A1/en active Pending
- 2017-03-31 JP JP2018551413A patent/JP6865767B2/en active Active
- 2017-03-31 KR KR1020207027488A patent/KR20200113290A/en not_active Application Discontinuation
- 2017-03-31 EP EP17776787.8A patent/EP3436072A4/en active Pending
- 2017-03-31 IL IL262021A patent/IL262021B2/en unknown
- 2017-03-31 MX MX2018011648A patent/MX2018011648A/en unknown
- 2017-03-31 CA CA3018774A patent/CA3018774C/en active Active
- 2017-03-31 AU AU2017240129A patent/AU2017240129B2/en active Active
- 2017-03-31 BR BR112018069732A patent/BR112018069732A2/en unknown
- 2017-03-31 GE GEAP201714913A patent/GEP20237466B/en unknown
- 2017-03-31 IL IL305200A patent/IL305200A/en unknown
- 2017-03-31 MA MA044518A patent/MA44518A/en unknown
- 2017-03-31 MY MYPI2018001577A patent/MY195432A/en unknown
- 2017-03-31 CN CN202311390678.0A patent/CN117582494A/en active Pending
- 2017-03-31 SG SG11201808242UA patent/SG11201808242UA/en unknown
- 2017-03-31 EA EA202191185A patent/EA202191185A1/en unknown
- 2017-03-31 EA EA201892218A patent/EA201892218A1/en unknown
-
2018
- 2018-09-24 PH PH12018502046A patent/PH12018502046A1/en unknown
- 2018-09-24 MX MX2022012380A patent/MX2022012380A/en unknown
- 2018-09-25 CL CL2018002708A patent/CL2018002708A1/en unknown
-
2020
- 2020-03-05 AU AU2020201633A patent/AU2020201633B2/en active Active
- 2020-04-22 JP JP2020075784A patent/JP2020125332A/en active Pending
-
2022
- 2022-05-27 JP JP2022086774A patent/JP2022110159A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808242UA (en) | Methods for inhibiting angiogenesis in a subject in need thereof | |
| SG11201810883TA (en) | Combination therapy | |
| SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201900606VA (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201909081YA (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
| SG11201900745VA (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
| SG11201811292RA (en) | Compositions and methods for the depletion of cells | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201901444PA (en) | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods | |
| SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
| SG11201805048SA (en) | Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia | |
| SG11201803834UA (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201903785TA (en) | Bivalent antibodies masked by coiled coils | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201809764XA (en) | Humanized anti-il-1r3 antibodies | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
| SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same |